{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:19:03Z","timestamp":1788542343279,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12328-025-02153-8","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T04:28:10Z","timestamp":1748838490000},"page":"626-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-3798","authenticated-orcid":false,"given":"Natsuki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2153_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.it.2012.01.003","volume":"33","author":"SJ Rubino","year":"2012","unstructured":"Rubino SJ, Geddes K, Girardin SE. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol. 2012;33:112\u20138. https:\/\/doi.org\/10.1016\/j.it.2012.01.003.","journal-title":"Trends Immunol"},{"key":"2153_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585\u2013600. https:\/\/doi.org\/10.1038\/nri3707.","journal-title":"Nat Rev Immunol"},{"key":"2153_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","volume":"129","author":"RM Onishi","year":"2010","unstructured":"Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129:311\u201321. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03240.x.","journal-title":"Immunology"},{"key":"2153_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1189\/jlb.0212101","volume":"92","author":"MM Elloso","year":"2012","unstructured":"Elloso MM, Gomez-Angelats M, Fourie AM. Targeting the Th17 pathway in psoriasis. J Leukoc Biol. 2012;92:1187\u201397. https:\/\/doi.org\/10.1189\/jlb.0212101.","journal-title":"J Leukoc Biol"},{"key":"2153_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379\u201390. https:\/\/doi.org\/10.1007\/s12016-018-8702-3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2153_CR6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191397","volume":"217","author":"I Prinz","year":"2020","unstructured":"Prinz I, Sandrock I, Mrowietz U. Interleukin-17 cytokines: effectors and targets in psoriasis-A breakthrough in understanding and treatment. J Exp Med. 2020;217: e20191397. https:\/\/doi.org\/10.1084\/jem.20191397.","journal-title":"J Exp Med"},{"key":"2153_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"key":"2153_CR8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing Brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1503824.","journal-title":"N Engl J Med"},{"key":"2153_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1512711.","journal-title":"N Engl J Med"},{"key":"2153_CR10","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/cimb44050127","volume":"44","author":"L \u021aiburc\u0103","year":"2022","unstructured":"\u021aiburc\u0103 L, Bembea M, Zaha DC, et al. The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases. Curr Issues Mol Biol. 2022;44:1851\u201366. https:\/\/doi.org\/10.3390\/cimb44050127.","journal-title":"Curr Issues Mol Biol"},{"key":"2153_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100104","volume":"4","author":"S Akiyama","year":"2021","unstructured":"Akiyama S, Sakuraba A. Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases. J Transl Autoimmun. 2021;4: 100104. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100104.","journal-title":"J Transl Autoimmun"},{"key":"2153_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","volume":"29","author":"M Hohenberger","year":"2018","unstructured":"Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29:13\u20138. https:\/\/doi.org\/10.1080\/09546634.2017.1329511.","journal-title":"J Dermatolog Treat"},{"key":"2153_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214273.","journal-title":"Ann Rheum Dis"},{"key":"2153_CR14","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693\u2013700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668.","journal-title":"Gut"},{"key":"2153_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2016;111:1599\u2013607. https:\/\/doi.org\/10.1038\/ajg.2016.298.","journal-title":"Am J Gastroenterol"},{"key":"2153_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","volume":"19","author":"MK Smith","year":"2019","unstructured":"Smith MK, Pai J, Panaccione R, et al. Crohn\u2019s-like disease in a patient exposed to anti-interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19:162.","journal-title":"BMC Gastroenterol"},{"key":"2153_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12876-020-01474-x","volume":"20","author":"J Ju","year":"2020","unstructured":"Ju J, Dai Y, Yang J, et al. Crohn\u2019s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. BMC Gastroenterol. 2020;20:340.","journal-title":"BMC Gastroenterol"},{"key":"2153_CR18","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.3748\/wjg.v29.i32.4912","volume":"29","author":"K Saito","year":"2023","unstructured":"Saito K, Yoza K, Takeda S, et al. Drug-induced entero-colitis due to interleukin-17 inhibitor use; capsule endoscopic findings and pathological characteristics: a case report. World J Gastroenterol. 2023;29:4912\u20139.","journal-title":"World J Gastroenterol"},{"key":"2153_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41395-018-0422-z","volume":"114","author":"M Vernero","year":"2019","unstructured":"Vernero M, Astegiano M, Ribaldone DG. New onset of inflammatory bowel disease in three patients undergoing IL-17A inhibitor secukinumab: a case series. Am J Gastroenterol. 2019;114:179\u201380. https:\/\/doi.org\/10.1038\/s41395-018-0422-z. (PMID: 30429591).","journal-title":"Am J Gastroenterol"},{"key":"2153_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.51821\/87.3.12874","volume":"87","author":"J Geldof","year":"2024","unstructured":"Geldof J, Truyens M, Strubbe B, et al. New onset inflammatory bowel disease after initiation of anti-IL-17a treatment: a case series. Acta Gastroenterol Belg. 2024;87:413\u20137. https:\/\/doi.org\/10.51821\/87.3.12874. (PMID: 39411795).","journal-title":"Acta Gastroenterol Belg"},{"key":"2153_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Li S, Ying S, et al. The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11: 594735.","journal-title":"Front Immunol"},{"key":"2153_CR22","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.4049\/jimmunol.1202122[EPub]","volume":"190","author":"SY Wu","year":"2013","unstructured":"Wu SY, Yu JS, Liu FT, et al. Galectin-3 negatively regulates dendritic cell production of IL-23\/IL-17-axis cytokines in infection by Histoplasma capsulatum. J Immunol. 2013;190:3427\u201337. https:\/\/doi.org\/10.4049\/jimmunol.1202122[EPub]. (PMID: 23455499).","journal-title":"J Immunol"},{"key":"2153_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","volume":"43","author":"JS Lee","year":"2015","unstructured":"Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-Independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43:727\u201338.","journal-title":"Immunity"},{"key":"2153_CR24","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019haens","year":"2023","unstructured":"D\u2019haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355.","journal-title":"N Engl J Med"},{"key":"2153_CR25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.21743","volume":"187","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Kimball AB, Augustin M, et al. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br J Dermatol. 2022;187:866\u201377.","journal-title":"Br J Dermatol"},{"key":"2153_CR26","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng Z, Wang S, Wu C, et al. IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis. Front Pharmacol. 2023;14:1124628.","journal-title":"Front Pharmacol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02153-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02153-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02153-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:49:29Z","timestamp":1757177369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02153-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02153-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest related to the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent for the publication of this case report was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}